within Pharmacolibrary.Drugs.ATC.S;

model S01EC03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.03,
    Cl             = 1.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,
    adminCount     = 1,
    Vd             = 0.00015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Dorzolamide is a carbonic anhydrase inhibitor primarily used as an ophthalmic solution to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is approved and widely used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers (ophthalmic administration). Dorzolamide accumulates in erythrocytes due to high affinity for carbonic anhydrase II. Minimal systemic exposure due to local ocular administration.</p><h4>References</h4><ol><li><p>Martens-Lobenhoffer, J, &amp; Banditt, P (2002). Clinical pharmacokinetics of dorzolamide. <i>Clinical pharmacokinetics</i> 41(3) 197–205. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200241030-00004&quot;>10.2165/00003088-200241030-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11929320/&quot;>https://pubmed.ncbi.nlm.nih.gov/11929320</a></p></li><li><p>Frampton, JE, &amp; Perry, CM (2006). Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. <i>Drugs &amp; aging</i> 23(12) 977–995. DOI:<a href=&quot;https://doi.org/10.2165/00002512-200623120-00005&quot;>10.2165/00002512-200623120-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17154662/&quot;>https://pubmed.ncbi.nlm.nih.gov/17154662</a></p></li><li><p>Kadam, RS, et al., &amp; Kompella, UB (2011). Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 39(9) 1529–1537. DOI:<a href=&quot;https://doi.org/10.1124/dmd.111.040055&quot;>10.1124/dmd.111.040055</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21673129/&quot;>https://pubmed.ncbi.nlm.nih.gov/21673129</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01EC03;
